In a post hoc analysis of the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) trial, including 1513 patients with type 2 diabetes and nephropathy with a mean follow-up time of 3.4 years, patients with high baseline albuminuria (≥3 g/g creatinine) levels had a 2.7-fold increased risk of incident HF compared with patients with low albuminuria [18]. This evidence concerns the gene AGT and type 2 diabetes mellitus.